The Medipattern Corporation

The Medipattern Corporation

May 22, 2009 06:30 ET

Medipattern® Begins B-CAD® Shipments to China

China Primary Health Care Foundation Starts Training on B-CAD as Integral Part of its National Breast Screening Program

TORONTO, ONTARIO--(Marketwire - May 22, 2009) -

Attention: Business/Financial Editors

The Medipattern Corporation (TSX VENTURE:MKI), a pioneer in the development of medical software solutions that help improve imaging workflow and productivity, is pleased to announce that it has commenced shipments to the China Primary Health Care Foundation ("CPHCF") as part of the CPHCF's purchase order for two hundred (200) B-CAD systems, as previously announced in December 2008. The CPHCF is purchasing the equipment for a pilot breast-screening program in hospitals throughout rural China. Training on the use of B-CAD and the ultrasound systems for the first 60 hospitals will be conducted on May 23rd in Beijing. Ten systems are being sent to CPHCF in this first block shipment as installation and training in the hospitals begins to roll-out.

Delivery and installation of the B-CAD software systems was delayed from the first quarter of 2009, due to a new audit policy by the National Audit Office in China for all public projects and their recent reforms to the National Health Policy.

As originally announced, Medipattern will receive a portion of the value of the contract in the form of a down payment, followed by further payments totaling 90 percent of the value of the shipments upon receipt of the software in China. Additional financial and operational details of the transaction were not disclosed, as stated in the original agreement, to maintain price security.

"Breast density has been a limiting factor in being able to perform screening in the People's Republic of China. Recent studies show that breast ultrasound imaging is more effective on dense breast types than screening mammography. In our practice, B-CAD is a necessary part of every breast ultrasound exam and as such we include it with every ultrasound unit that we order for breast diagnosis and screening," commented Dr. Tang Jie, Director of Ultrasound for the PLA 301 in Beijing. "Breast ultrasound is a central part of our screening program in China."

Breast cancer is a significant issue in China. The incidence of breast cancer has increased by at least 27 percent over the past decade, and 40 percent of the Chinese women diagnosed with breast cancer die within five years because the cancer is already very advanced when it is diagnosed according to Lino et al., in the paper "Effects Of Reproductive And Demographic Changes On Breast Cancer Incidence In China: A Modeling Analysis" Journal Of National Cancer Institute 2008; 100: 1339-41. According to these models Shanghai has the highest incidence of breast cancer in China and will continue to have the highest number of cases until 2021. More than sixty (60) in every hundred thousand (100,000) women in the city is diagnosed with the disease, which is three times higher than the incidence rate in the United States and Canada. Approximately 6.4 percent of those patients who are diagnosed with breast cancer are under the age of thirty-five (35).

"Medipattern continues to be an active advocate for the screening and early diagnosis of breast cancer in China through providing educational courses and participating in studies that would help determine effective means to screen for breast cancer. In a study by Dr. Li et al., (American Journal of Clinical Oncology, Volume 31, Number 5, October 2008, pg. 515) performed at China's premier hospital, the PLA 301, B-CAD was found to increase diagnostic accuracy by 44 percent in lesions less than 1cm in size," stated Jeff Collins, CEO of Medipattern. "Training is under way in China for this project and we expect to get back on track for shipments on this order as the training progresses. We congratulate our business partners at Beijing Eastwide Medical Ltd. in negotiating and facilitating this transaction."

About The Medipattern Corporation:

Medipattern® is a pioneer in the development of medical software solutions that help improve imaging workflow and productivity. Our first-to-market, award-winning B-CAD® advances breast ultrasound computer aided detection (CAD) by streamlining workflow and organizing information into a comprehensive patient record. Medipattern uses its Cadenza™ CAD Technology to power the digital conversion in medical communications. B-CAD automatically creates fully digital standardized worksheets and reports that make every practice more efficient, productive and ultimately more effective. For more information, please visit the company's website at:

B-CAD® and Medipattern® are a registered mark of The Medipattern Corporation.

Forward-looking statements

This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential", and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings, (posted at In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release and has neither approved nor disapproved of the contents of this release.

Contact Information